Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Summary

This phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2012-11-14

Primary completion

2018-12-31

Completion

2019-12-31

Drugs

Indications